Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238407 | 0.79 | HTR7 (0.53) | SLC6A2HTR7KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL236730 | 0.79 | SLC6A2 (0.47) | SLC6A2SSTR4PDE5AKDM4EALDH1A1 | |
| SCHEMBL5585616 | 0.78 | KDM4E (0.47) | SLC6A2HTR7KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5586046 | 0.77 | KDM4E (0.52) | SLC6A2HTR7KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4318642 | 0.77 | CHRNB4 (0.48) | SLC6A2PDE5AALDH1A1SMN1; SMN2CYP11B1 | |
| SCHEMBL5585671 | 0.75 | SLC6A2 (0.46) | SLC6A2PDE5AHTR7SYKKDM4E | |
| SCHEMBL5585621 | 0.74 | SLC6A2 (0.62) | SLC6A2PDE5AKDM4EALDH1A1 | |
| SCHEMBL5585853 | 0.73 | CHRNB2 (0.49) | SLC6A2PDE5AHTR7 | |
| SCHEMBL4307757 | 0.70 | CHRNB2 (0.46) | SLC6A2PDE5AKDM4EALDH1A1IDO1 | |
| SCHEMBL23344983 | 0.69 | SLC6A2 (0.41) | SLC6A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | SLC6A2 23/4885SSTR4 241/4885PDE5A 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.